• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Precision Optics Launches Revolutionary Unity Imaging Platform

    1/28/25 9:00:00 AM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $POCI alert in real time by email

    GARDNER, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation (NASDAQ:POCI), a global leader in the design and development of optical components and systems for advanced medical, industrial, and defense/aerospace applications, is pleased to announce the launch of the Unity Imaging Platform, comprising a standard baseline CMOS endoscopic system with customization options based on existing or newly designed sub-components. This groundbreaking modular optical platform is set to transform the development and production of endoscopic imaging devices by significantly reducing costs, time to market, and project risks.

    A Platform Built on a Depth of Experience

    The Unity Imaging Platform ("Unity") represents the culmination of many years of research, development, and collaboration with key industry players. By leveraging insights from many previous projects, Unity incorporates proven design architectures to meet the unique needs of today's medical imaging devices. Customers benefit from a modular, adaptable solution that simplifies every stage of the development process, from prototyping to production using the latest technologies.

    "The Unity platform embodies Precision Optics' deep expertise in CMOS-based imaging systems and our commitment to accelerating innovation in medical technology," said Dr. Joe Forkey, CEO of Precision Optics. "By consolidating common design elements and offering a flexible, modular architecture, appropriate for both re-usable and single-use endoscopic systems, Unity enables faster, more cost-effective development while maintaining the very highest standards of quality and compliance."

    Revolutionizing the One Customer, One Device Approach

    Traditionally, optical development in medical imaging has been highly customized, with each solution tailored to the specific needs of an individual project. While effective, this approach often results in long development cycles and higher costs. Unity flips this model on its head by delivering a robust, adaptable system that serves as a foundation for entire families of products.

    Jonathan Everett, Vice President of Engineering at Precision Optics, explained, "With Unity, we're able to provide customers with a functional video pipeline early in the development process. This accelerates their system integration efforts and allows them to gather feedback from stakeholders much sooner, ultimately shortening the time to market and enhancing overall project efficiency."

    Key Benefits of the Unity Imaging Platform

    • Accelerated Time to Market: Customers can begin system integration and user testing earlier, reducing development cycles and speeding up the path to production.
    • Cost Efficiency: By leveraging pre-validated design elements, customers minimize the need for bespoke engineering efforts, resulting in potential cost savings as the risks of redesign are low.
    • Risk Mitigation: Unity's proven architectures reduce the uncertainties inherent in developing novel imaging devices, ensuring regulatory compliance and robust performance.
    • Scalability: The platform supports the development of multiple products from a single design framework, offering scalability for growing product portfolios.

    Driving Innovation in Single-Use Endoscopy

    Single-use endoscopic devices are a rapidly growing segment within medical imaging, offering significant benefits in terms of safety and cost-effectiveness. Unity uniquely suits this market, providing an ideal foundation for developing disposable imaging solutions.

    "Our recent production launches of single-use endoscopes showcase the power of our technology to meet the stringent cost and performance demands of this sector," Dr. Forkey noted. "With two programs already in production and more in development, we are driving advancements that benefit patients, healthcare providers, and device manufacturers alike."

    An Accelerated Approach to Cutting-Edge Solutions

    Precision Optics has a long-standing reputation for fostering collaborative partnerships with its customers. Unity enhances these relationships by offering a shared vision for innovation and a pathway to market success. Early adopters of Unity have expressed enthusiasm about its accelerated, streamlined development process and potential to expand their product capabilities.

    "The response from our key partners has been very positive," Dr. Forkey said. "By thinking beyond individual projects and embracing a standardized approach, our customers can unlock new opportunities for growth and innovation."

    Looking Ahead

    With the launch of Unity, Precision Optics is poised to lead the next generation of optical innovation. Upcoming platform expansions will include advanced capabilities such as multi-sensor imaging for 3D and fluorescence applications, enabling groundbreaking medical procedures that improve patient outcomes.

    "Unity is not just a platform; it's premised on a philosophy of continuous improvement," Everett added. "We're excited to work with our customers to bring new levels of performance, efficiency, and impact to medical imaging."

    About Precision Optics Corporation

    Founded in 1982, Precision Optics is a vertically integrated optics company primarily focused on leveraging its proprietary micro-optics and 3D imaging technologies to the healthcare and defense/aerospace industries by providing services ranging from new product concept through mass manufacture. Utilizing its leading-edge in-house design, prototype, regulatory and fabrication capabilities as well as its Lighthouse Imaging division's electronic imaging expertise and its Ross Optical division's high volume world-wide sourcing, inspecting and production resources, the Company designs and manufactures next-generation product solutions for the most challenging customer requirements. Within healthcare, Precision Optics enables next generation medical device companies around the world to meet the increasing demands of the surgical community who require more enhanced and smaller imaging systems for minimally invasive surgery, including single-use medical devices, as well as 3D endoscopy systems to support the rapid proliferation of surgical robotic systems. In addition to these next generation applications, Precision Optics has supplied top tier medical device companies with a wide variety of optical products for decades, including complex endocouplers and specialized endoscopes. The Company is also leveraging its technical proficiency in micro-optics to enable leading edge defense/aerospace applications which require the highest quality standards and the optimization of size, weight and power. For more information, please visit www.poci.com.

    About Forward-Looking Statements

    This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements which express the Company's intentions, beliefs, expectations, strategies, predictions or any other statements related to the Company's future activities or future events or conditions. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by the Company's management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement, except as required by law.

    Company Contact:

    Clay Schwabe

    Precision Optics Corporation

    22 East Broadway

    Gardner, Massachusetts 01440-3338

    Telephone: 978-630-1800

    Investor Contact:

    LYTHAM PARTNERS, LLC

    Robert Blum

    Telephone: 602-889-9700

    [email protected]



    Primary Logo

    Get the next $POCI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $POCI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $POCI
    SEC Filings

    View All

    SEC Form S-8 filed by Precision Optics Corporation Inc.

    S-8 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Filer)

    12/3/25 4:16:06 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Precision Optics Corporation Inc.

    SCHEDULE 13G/A - PRECISION OPTICS CORPORATION, INC. (0000867840) (Subject)

    11/21/25 5:30:20 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-Q filed by Precision Optics Corporation Inc.

    10-Q - PRECISION OPTICS CORPORATION, INC. (0000867840) (Filer)

    11/13/25 4:15:47 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $POCI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Precision Optics Reports First Quarter Fiscal Year 2026 Financial Results

    GARDNER, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, announced operating results on an unaudited basis for its first quarter fiscal year 2026 for the period ended September 30, 2025. Q1 2026 Financial Highlights (3 Months Ended September 30, 2025): Revenue was $6.7 million, a quarterly record, compared to $4.2 million in the same quarter of the previous fiscal year, representing growth of approximately 59%.Production revenue was $6.0 million, a quarterly record, compared to $2.6 million in the same quarter of the previous fis

    11/13/25 4:30:00 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Precision Optics Announces Product Development Agreement to Develop Custom High-End Borescope for Jet Engines

    GARDNER, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced the receipt of a product development order to design and build a next generation borescope system to be used to inspect the inside of jet engines from a large aerospace and defense company. The system involves the development of a high-end, small-diameter borescope designed in multiple configurations to measure critical components inside jet engines in the field. It will deliver greater-than-1080p HD resolution performance and is engineered to withstand the e

    11/11/25 9:00:00 AM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Precision Optics Announces Product Development Agreement to Deliver Next-Generation Augmented Reality Sub-Systems for Fighter Pilots

    GARDNER, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced the receipt of a product development order to build sub-assemblies that will support an advanced augmented reality (AR) system for US Air Force fighter pilot training, powered by POC's next-generation optical sub-assembly design and manufacturing technologies. The program aims to allow pilots to wear AR headsets while in the air in their fighter jets, simulating combat training, without the need for secondary aircraft to be present. This reduces cost and the

    11/7/25 9:00:00 AM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $POCI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Pellegrino Joseph P Jr

    4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

    11/19/25 9:11:13 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Director Woodward Peter H

    4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

    11/19/25 4:34:59 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Director Miclot Andrew J.

    4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

    11/19/25 4:34:46 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $POCI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Coll Wayne M bought $107,905,271 worth of shares (4,317 units at $24,995.43) (SEC Form 4)

    4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

    8/16/24 4:30:31 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Executive Officer Forkey Joseph Norman bought $17,228,869 worth of shares (1,725 units at $9,987.75), increasing direct ownership by 1% to 122,572 units (SEC Form 4)

    4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

    8/16/24 4:30:30 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Operating Officer Lawande Mahesh bought $17,248,850 worth of shares (1,726 units at $9,993.54) (SEC Form 4)

    4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

    8/16/24 4:30:33 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $POCI
    Leadership Updates

    Live Leadership Updates

    View All

    Precision Optics Appoints Joseph P. Pellegrino, Jr. to Board of Directors

    GARDNER, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, is pleased to announce the appointment of Joseph P. "JJ" Pellegrino, Jr. to its Board of Directors. Mr. Pellegrino, who will also serve as Chairman of the Board's Audit Committee, brings decades of operational and financial experience as well as an extensive knowledge of the medical device industry to the board. Mr. Pellegrino most recently served as Chief Financial Officer of LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of devices, implants and services for the treatm

    3/20/25 9:00:00 AM ET
    $LMAT
    $POCI
    Medical/Dental Instruments
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    Precision Optics Appoints Buell Duncan to Board of Directors; Dr. Richard Miles Retires from Board

    GARDNER, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, is pleased to announce the appointment of Buell Duncan to its Board of Directors. Mr. Duncan brings decades of executive leadership and strategic expertise, further strengthening the Company's commitment to innovation and growth. With an extensive career in the technology and business sectors, Mr. Duncan held senior leadership positions at a number of IBM global business units from 1992 through 2020 where he was instrumental in driving marketing, strategy, and business deve

    3/4/25 4:30:00 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Precision Optics Appoints Clay Schwabe as VP of Sales and Marketing

    GARDNER, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, today announced the appointment of Clay Schwabe, as the Company's Vice President of Sales and Marketing. Mr. Schwabe has over fifteen years of experience in medical device market access, sales, sales management, global product marketing, and commercialization. He is an emerging technologies specialist with experience in early-stage commercialization of minimally invasive surgical products and procedures. Most recently, he served as VP Business Development, Commercial Strategy, CRO, an

    7/8/24 9:00:00 AM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $POCI
    Financials

    Live finance-specific insights

    View All

    Precision Optics Schedules First Quarter of Fiscal Year 2026 Conference Call for November 13, 2025

    GARDNER, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has scheduled a conference call to discuss the Company's first quarter fiscal year 2026 financial results on Thursday, November 13, 2025, at 5:00 p.m. ET. The Company intends to release its financial results and to file its 10-Q after the close of the market on Thursday, November 13, 2025, followed by the conference call. Conference Call Details Date and Time: Thursday, November 13, 2025, at 5:00 p.m. ET. Call-in Information: Intere

    11/6/25 4:15:00 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Precision Optics Schedules Fourth Quarter and Fiscal Year 2025 Conference Call for September 29, 2025

    GARDNER, Mass., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has scheduled a conference call to discuss the Company's fourth quarter and fiscal year 2025 financial results on Monday, September 29, 2025, at 5:00 p.m. ET. The Company intends to release its financial results and to file its 10-K after the close of the market on Monday, September 29, 2025, followed by the conference call. Conference Call Details Date and Time: Monday, September 29, 2025, at 5:00 p.m. ET. Call-in Information: Int

    9/24/25 4:15:00 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Precision Optics Schedules Third Quarter of Fiscal Year 2025 Conference Call for May 15, 2025

    GARDNER, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has scheduled a conference call to discuss the Company's third quarter fiscal year 2025 financial results on Thursday, May 15, 2025, at 5:00 p.m. ET. The Company intends to release its financial results and to file its 10-Q after the close of the market on Thursday, May 15, 2025, followed by the conference call. Conference Call Details Date and Time: Thursday, May 15, 2025, at 5:00 p.m. ET. Call-in Information: Interested par

    5/8/25 4:15:00 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $POCI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Precision Optics Corporation Inc.

    SC 13G/A - PRECISION OPTICS CORPORATION, INC. (0000867840) (Subject)

    11/13/24 5:53:45 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Precision Optics Corporation Inc.

    SC 13G - PRECISION OPTICS CORPORATION, INC. (0000867840) (Subject)

    5/17/24 5:03:18 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care